Skinvisible Reveals Promising Transdermal Obesity Data

Skinvisible Pharmaceuticals, Inc., a pioneering company in topical pharmaceutical research and development, has released promising data on the transdermal delivery of obesity and glucose-controlling drugs using its proprietary Invisicare® technology. Invisicare is a polymer delivery vehicle that negates the need for patches or needles. The company has filed two provisional patent applications for formulations that utilize Invisicare for the transdermal administration of these drugs.

Skinvisible's research has focused on creating topical formulations that allow these drugs to be absorbed through the skin and into the bloodstream, offering a sustained release over time. The results of their studies are noteworthy:

- Franz Cell diffusion studies indicated that the GLP-1 agonist drug achieved a penetration rate of up to 69% over six hours.
- For the CB-1 receptor antagonists formulated with Invisicare, a 62% penetration rate was recorded over the same period.
- Additionally, the Invisicare formulations demonstrated the ability to provide sustained drug delivery, with an average drug release of about 10% per hour.

These findings suggest that Invisicare technology can be applied to a wider range of GLP-1 agonists and CB-1 receptor antagonists, provided their molecular mass allows for transdermal penetration. This advancement presents significant opportunities for expanding Skinvisible's portfolio of obesity-targeting formulations.

Terry Howlett, CEO of Skinvisible, elaborated on the potential impact of Invisicare technology. He highlighted that this innovation could transform the administration of obesity drugs by delivering substantial amounts of medication systemically. This method could potentially avoid the side effects associated with oral pills and injections, thus increasing patient compliance. Howlett explained that oral pills often face extensive metabolism in the digestive system and liver before reaching their targets, which can lead to uncomfortable side effects. In contrast, injections are often painful and can contribute to poor patient compliance. The topical cream formulations developed by Skinvisible offer a transdermal approach that bypasses first-pass metabolism and related challenges, making them a viable option for maintenance therapy.

Skinvisible's focus on the obesity market aligns with the rising global need for effective obesity treatments. A recent IQVIA report predicts that by 2035, 25% of the global population will be obese. Correspondingly, the global obesity market is expected to grow from $24 billion in 2023 to an astonishing $131 billion by 2028.

To advance its transdermal obesity therapies, Skinvisible is seeking strategic partnerships with pharmaceutical or biotech companies. These collaborations aim to bring the first transdermal obesity treatments to market and explore other potential applications of its transdermal delivery platform in various disease areas.

Skinvisible Pharmaceuticals, Inc., a wholly-owned subsidiary of Skinvisible, Inc., specializes in licensing proprietary topical and transdermal formulations utilizing its patented polymer skin delivery system, Invisicare. The technology allows for effective adhesion of active ingredients to the skin, enabling controlled release into the bloodstream over time. Skinvisible has developed formulations for obesity treatment and over forty dermatology-related conditions, including rare skin disorders.